Literature DB >> 30739104

Association between Peripheral Artery Disease and Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome: Findings from the Gulf COAST Registry.

Ibrahim Al-Zakwani1,2,3, Ekram Al Siyabi4, Najib Alrawahi5, Arif Al-Mulla6, Abdullah Alnaeemi7, Abdulla Shehab8, Mohammad Zubaid9.   

Abstract

OBJECTIVE: To evaluate the association between peripheral artery disease (PAD) and major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) in the Arabian Gulf.
METHODS: Data from 4,044 consecutive patients diagnosed with ACS admitted to 29 hospitals in four Arabian Gulf countries from January 2012 to January 2013 were analyzed. PAD was defined as any of the following: claudication, amputation for arterial vascular insufficiency, vascular reconstruction, bypass surgery, or percutaneous intervention in the extremities, documented aortic aneurysm or an ankle brachial index of <0.8 in any of the legs. MACE included stroke/transient ischemic attack (TIA), myocardial infarction (MI), all-cause mortality, and readmissions for cardiac reasons diagnosed between hospital admission and at 1-year post discharge. Analyses were performed using univariate and multivariate statistical techniques.
RESULTS: The overall mean age of the cohort was 60 ± 13 years and 66% (n = 2,686) were males. A total of 3.3% (n = 132) of the patients had PAD. Patients with PAD were more likely to be associated with smoking, prior MI, hypertension, diabetes mellitus, and stroke/TIA. At the 1-year follow-up, patients with PAD were significantly more likely to have MACE (adjusted OR [aOR], 2.07; 95% confidence interval [CI]: 1.41-3.06; p< 0.001). The higher rates of events were also observed across all MACE components; stroke/TIA (aOR, 3.22; 95% CI: 1.80-5.75; p< 0.001), MI (aOR, 2.15; 95% CI: 1.29-3.59; p =0.003), all-cause mortality (aOR, 2.21; 95% CI: 1.33-3.69; p =0.002), and readmissions for cardiac reasons (aOR, 1.83; 95% CI: 1.24-2.70; p =0.003).
CONCLUSIONS: PAD was significantly associated with MACE in ACS patients in the Arabian Gulf.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute coronary syndrome; Arabs; Middle East; Mortality; Myocardial infarction; Peripheral artery disease; Stroke; Transient ischemic attack

Mesh:

Year:  2019        PMID: 30739104      PMCID: PMC6771062          DOI: 10.1159/000497790

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  30 in total

1.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; James Patrick Zidar
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

2.  ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards.

Authors:  William S Weintraub; Ronald P Karlsberg; James E Tcheng; Jeffrey R Boris; Alfred E Buxton; James T Dove; Gregg C Fonarow; Lee R Goldberg; Paul Heidenreich; Robert C Hendel; Alice K Jacobs; William Lewis; Michael J Mirro; David M Shahian
Journal:  J Am Coll Cardiol       Date:  2011-06-07       Impact factor: 24.094

3.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).

Authors:  Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais
Journal:  Eur Heart J       Date:  2018-03-01       Impact factor: 29.983

4.  Peripheral arterial disease and progression of coronary atherosclerosis.

Authors:  Ayman A Hussein; Kiyoko Uno; Kathy Wolski; Samir Kapadia; Paul Schoenhagen; E Murat Tuzcu; Steven E Nissen; Stephen J Nicholls
Journal:  J Am Coll Cardiol       Date:  2011-03-08       Impact factor: 24.094

5.  Multicenter cross-sectional study of asymptomatic peripheral arterial disease among patients with a single previous coronary or cerebrovascular event in the Arabian Gulf.

Authors:  Amit Kumar; Marzouk Al-Bader; Hassan Al-Thani; Ayman El-Menyar; Jassim Al Suwaidi; Ibrahim Al-Zakwani; Dirk Deleu; Mohammed Ismail
Journal:  Curr Med Res Opin       Date:  2014-06-05       Impact factor: 2.580

6.  Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.

Authors:  Andrew T Yan; Raymond T Yan; Mary Tan; Thao Huynh; Kamyar Soghrati; Lawrence J Brunner; Paul DeYoung; David H Fitchett; Anatoly Langer; Shaun G Goodman
Journal:  Am Heart J       Date:  2007-09-14       Impact factor: 4.749

7.  Factors affecting the validity of ankle-brachial index in the diagnosis of peripheral arterial obstructive disease.

Authors:  Su Chung Nam; Seung Hwan Han; Sang Hyun Lim; You Sun Hong; Je Hwan Won; Jae Ik Bae; Joon Jo
Journal:  Angiology       Date:  2009-09-16       Impact factor: 3.619

8.  Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.

Authors:  Yufang Bi; Runlin Gao; Anushka Patel; Steve Su; Wei Gao; Dayi Hu; Dejia Huang; Lingzhi Kong; Wenhang Qi; Yangfeng Wu; Yuejin Yang; Fiona Turnbull
Journal:  Am Heart J       Date:  2008-12-17       Impact factor: 4.749

9.  Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA).

Authors:  Manuel Monreal; Lorenzo Alvarez; Blanca Vilaseca; Ramón Coll; Carmen Suárez; Jesús Toril; Carmen Sanclemente
Journal:  Eur J Intern Med       Date:  2007-10-31       Impact factor: 4.487

10.  Long-term cardiovascular outcome, use of resources, and healthcare costs in patients with peripheral artery disease: results from a nationwide Swedish study.

Authors:  Pål Hasvold; Joakim Nordanstig; Björn Kragsterman; Thomas Kristensen; Mårten Falkenberg; Saga Johansson; Marcus Thuresson; Birgitta Sigvant
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-01-01
View more
  1 in total

1.  The Association of Fractional Pulse Pressure with Acute Kidney Injury in Patients Undergoing Coronary Intervention due to ST-Segment Elevated Myocardial Infarction.

Authors:  Cengiz Burak; Muhammed Süleymanoğlu; Mahmut Yesin; Murat Cap; İbrahim Yıldız; İbrahim Rencüzoğulları; Metin Çağdaş; Yavuz Karabağ; Şerif Hamideyin; Doğan İliş; Erkan Baysal
Journal:  Med Princ Pract       Date:  2020-04-28       Impact factor: 1.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.